These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 8620676

  • 1. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
    Wong SL, Awni WM, Cavanaugh JH, el-Shourbagy T, Locke CS, Dubé LM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676
    [Abstract] [Full Text] [Related]

  • 2. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.
    Awni WM, Cavanaugh JH, Braeckman RA, Chu SY, Patterson KJ, Machinist JM, Granneman GR.
    Clin Pharmacokinet; 1995; 29 Suppl 2():49-61. PubMed ID: 8620671
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic interactions between zileuton and prednisone.
    Awni WM, Cavanaugh JH, Tzeng TB, Witt G, Granneman GR, Dubé LM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():105-11. PubMed ID: 8620666
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The pharmacokinetics of zileuton in healthy young and elderly volunteers.
    Braeckman RA, Granneman GR, Locke CS, Machinist JM, Cavannaugh JH, Awni WM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():42-8. PubMed ID: 8620670
    [Abstract] [Full Text] [Related]

  • 7. Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.
    Granneman GR, Braeckman RA, Erdman KA.
    Clin Pharmacokinet; 1995; 29 Suppl 2():1-8. PubMed ID: 8620665
    [Abstract] [Full Text] [Related]

  • 8. Effect of zileuton on theophylline pharmacokinetics.
    Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dubé LM, Awni WM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():77-83. PubMed ID: 8620674
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
    Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, Dubé LM.
    Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667
    [Abstract] [Full Text] [Related]

  • 16. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
    Machinist JM, Mayer MD, Shet MS, Ferrero JL, Rodrigues AD.
    Drug Metab Dispos; 1995 Oct; 23(10):1163-74. PubMed ID: 8654206
    [Abstract] [Full Text] [Related]

  • 17. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
    Awni WM, Hussein Z, Cavanaugh JH, Granneman GR, Dubé LM.
    Clin Pharmacokinet; 1995 Oct; 29 Suppl 2():92-7. PubMed ID: 8620677
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
    Awni WM, Granneman GR, Locke CS, Brandwein SR, Dube LM.
    Eur J Clin Pharmacol; 1995 Oct; 48(2):155-60. PubMed ID: 7589031
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.